Clinical trials: Not Determined, open to volunteers
Treatment-resistant Schizophrenia
Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia
This is a prospective, 12-week, randomized, double-blind, placebo-controlled study, designed to evaluate the efficacy, safety, and tolerability of a dose of evenamide of 15 mg bid, compared to placebo, as add-on treatment in…
- Trial name
- ENIGMA-TRS 2 (NCT07184619)
- Testing
- Evenamide 15 mg bid
- Where
- 19 sites in United States, Argentina and 2 more
- Volunteers
- 400 people
- Sponsor
- Newron Pharmaceuticals SPA
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
This phase II MyeloMATCH treatment trial tests whether the standard approach of cytarabine and daunorubicin in comparison to the following experimental regimens works to shrink cancer in patients with high risk acute myeloid…
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related
- Trial name
- NCT05554406
- Testing
- Azacitidine, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 227 sites in United States, Canada and 1 more
- Volunteers
- 335 people
- Sponsor
- National Cancer Institute (NCI)
Attention Deficit Disorder, Attention Deficit Disorder (ADD)
The Primary Objective of This Study is to Determine Whether Positively Framed Information (PFI) on Side Effects, Compared to Negatively Framed and Extensive Information (NFI) Can Reduce the Number and Severity of Reported Adverse Events Caused by ADHD Medication in Children Aged 7 to 17 Years.
The goal of this randomized controlled care evaluation is to determine whether positively framed and concise information (PFI), compared to negatively framed and extensive information (NFI) about adverse events can reduce the…
- Conditions
- Attention Deficit Disorder, Attention Deficit Disorder (ADD), Attention Deficit Disorder with Hyperactivity, ADHD
- Trial name
- NOVA (NCT06797570)
- Testing
- Communication Strategy for Side Effect Counseling in ADHD Treatment
- Volunteers
- 130 people
- Sponsor
- St. Antonius Hospital
T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
This study evaluates a fenretinide phospholipid suspension for the treatment of T-cell non-Hodgkin's lymphoma (NHL).
- Conditions
- T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma, Peripheral T-Cell Lymphoma, Not Classified
- Trial name
- NCT04234048
- Testing
- Fenretinide
- Where
- 10 sites in United States
- Volunteers
- 46 people
- Sponsor
- SciTech Development, Inc.
Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap…
- Conditions
- Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified, Recurrent Atypical Chronic Myeloid Leukemia
- Trial name
- NCT05549661
- Testing
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Onvansertib
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Mayo Clinic